Literature DB >> 463998

Long-term course of chloroquine retinopathy after cessation of medication.

J R Brinkley, E L Dubois, S J Ryan.   

Abstract

Seven patients with chloroquine retinopathy were examined ten years after their therapy with chloroquine or hydroxychloroquine, or both, had been discontinued and an additional five patients with chloroquine retinopathy were similarly examined from two to eight years after their therapy had been discontinued. Visual acuity, visual fields, and ophthalmoscopic examinations were compared to those performed at the time therapy was discontinued. These long-term observations confirmed the previously published observations based on short-term studies that chloroquine retinopathy tends to remain stable after therapy is discontinued, although a few patients in the early stages of retinopathy may show regression and occasionally a patient with a more advanced stage of the disease may show progression.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 463998     DOI: 10.1016/0002-9394(79)90743-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  18 in total

Review 1.  [Progressive maculopathy despite discontinuation of chloroquine treatment-multimodal imaging and review of the literature].

Authors:  A Rickmann; S Al-Nawaiseh; L Ramirez; S Röhrig; M Ladewig; P Szurman; G Szurman
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

2.  Ocular toxicity from systemic drug therapy. An overview of clinically important adverse reactions.

Authors:  S I Davidson; I G Rennie
Journal:  Med Toxicol       Date:  1986 May-Jun

3.  Comparison between multifocal ERG and C-Scan SD-OCT ("en face" OCT) in patients with a suspicion of antimalarial retinal toxicity: preliminary results.

Authors:  Carl Arndt; Mathieu Costantini; Christophe Chiquet; Mickael Afriat; Sylvie Berthemy; Vivien Vasseur; Alain Ducasse; Martine Mauget-Faÿsse
Journal:  Doc Ophthalmol       Date:  2018-03-13       Impact factor: 2.379

4.  Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.

Authors:  Paul Salu; André Uvijls; Pierre van den Brande; Bart P Leroy
Journal:  Doc Ophthalmol       Date:  2010-04-16       Impact factor: 2.379

Review 5.  Adverse ocular reactions to drugs.

Authors:  M A Spiteri; D G James
Journal:  Postgrad Med J       Date:  1983-06       Impact factor: 2.401

6.  Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective.

Authors: 
Journal:  Ann Rheum Dis       Date:  1982       Impact factor: 19.103

Review 7.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

8.  Chloroquine retinopathy: is there a safe daily dose?

Authors:  J S Marks
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

Review 9.  Hydroxychloroquine retinopathy.

Authors:  I H Yusuf; S Sharma; R Luqmani; S M Downes
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

10.  Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.